Abstract: A system and method for determining a viscosity of a fluid medium containing a fluorescent species, including a light source exciting the fluorescent species at an excitation area of the fluid medium to produce a fluorescent signal and photobleaching the fluorescent species, and the fluorescent species diffusing in and out of the excitation area of the fluid medium at a rate determined by an excitation geometry of the light source, a diffusivity of the fluorescent species, and the viscosity of the fluid medium; and a detector detecting the fluorescent signal over time to generate a fluorescence decay curve of the fluorescent species in the fluid medium, where the viscosity of the fluid medium is determined based on a numerical comparison of the fluorescence decay curve of the fluorescent species in the fluid medium with a fluorescence decay curve of the fluorescent species in a reference medium of known viscosity.
Abstract: Described herein are methods and apparatuses for reducing or eliminating skin glands (e.g., sebaceous, eccrine and apocrine) with an electric treatment. These apparatuses and methods may produce electroporation of cells by applying treatment dose having an energy density sufficient to eliminate or reduce the size of a target gland. Also described herein are methods for treating and/or preventing a disorder of a skin gland. For example, described herein are methods of treating sebaceous hyperplasia.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
December 31, 2024
Assignee:
Pulse Biosciences, Inc.
Inventors:
Lauren M. Jauregui Johnston, Edward A. Ebbers, David J. Danitz, Richard L. Nuccitelli, Darrin R. Uecker, Kevin L. Moss, Cameron D. Hinman
Abstract: A method of treating osteoarthritis includes an implantable stimulator generating stimulation sessions at a duty cycle that is less than 0.05 and applying the stimulation sessions by way of the central electrode and the annular electrode to a location within a patient that includes at least one of an acupoint labeled ST35, an acupoint labeled EX-LE-4, or a location on a line that intersects the acupoints labeled ST35 and EX-LE-4.
Type:
Grant
Filed:
May 12, 2022
Date of Patent:
December 31, 2024
Assignee:
Valencia Bioscience, Inc.
Inventors:
Jeffrey H. Greiner, David K. L. Peterson, Stacy Greiner Chambliss
Abstract: Aspects relate to an automated cell culture incubator and to methods for using such an incubator. In one aspect, the cell culture incubator includes an incubator cabinet having a transfer chamber and an internal chamber that are arranged to form an airlock configuration. In some embodiments, objects placed into the incubator cabinet are sterilized using ozone produced by an ozone generator. The incubator may include one or more transfer devices that move objects between the transfer chamber and the internal chamber.
Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
Type:
Application
Filed:
August 14, 2024
Publication date:
December 26, 2024
Applicant:
Arcus Biosciences, Inc.
Inventors:
Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
Abstract: The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula (I): or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.
Abstract: Provided herein are methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies. Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
Type:
Grant
Filed:
September 23, 2020
Date of Patent:
December 24, 2024
Assignee:
Twist Bioscience, Inc.
Inventors:
Aaron Sato, Pankaj Garg, Qiang Liu, Tom Yuan
Abstract: The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
December 24, 2024
Assignee:
Ibex Biosciences, Inc.
Inventors:
Michael Joseph Karlin, Alberto Murat Croci, Vidal Felix De La Cruz, Norman Zhennan Lai, Roy Feinson
Abstract: This disclosure relates to linker polypeptides. In some embodiments, the linker polypeptide comprises a first targeting sequence; a second targeting sequence; and a first linker between the first targeting sequence and the second targeting sequence, the linker comprising a protease-cleavable polypeptide sequence. In some embodiments, the linker polypeptide comprises a first active domain; a second active domain; a pharmacokinetic modulator; and a first linker between the pharmacokinetic modulator and the first active domain, the first linker comprising a protease-cleavable polypeptide sequence. In some embodiments, the linker polypeptide comprises a first active domain; an inhibitory polypeptide sequence capable of blocking an activity of the first active domain; a first linker between the first active domain and the inhibitory polypeptide sequence, the linker comprising a protease-cleavable polypeptide sequence; and a first targeting sequence.
Type:
Application
Filed:
January 18, 2024
Publication date:
December 19, 2024
Applicant:
Trutino Biosciences Inc.
Inventors:
Phillip S. Kim, Emma Langley, Hsieng Lu, Xinjun Liu, Chen Li
Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
Type:
Grant
Filed:
April 8, 2024
Date of Patent:
December 17, 2024
Assignee:
Arcus Biosciences, Inc.
Inventors:
Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
Abstract: A method and apparatus for searching cell images comprising storing cell images in an image database, generating index data for the stored images in the image database, wherein the index data includes image metadata and data extracted from the stored image data by analysis including morphological descriptors, applications of algorithms, machine learning and/or data mining.
Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
Type:
Application
Filed:
May 8, 2024
Publication date:
December 12, 2024
Applicant:
Inhibrx Biosciences, Inc.
Inventors:
John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
Abstract: A cell incubator system comprising a housing having an internal chamber having a controlled temperature and gas mixture therein appropriate for the growth of particular cells for incubation of the particular cells in one or more cell culture vessels in the internal chamber and a plurality of cell operation stations in the internal chamber. The stations receive plates having wells for holding cells and wherein the cell operations stations perform operations on cells in the wells. The system has a robotic transport for moving plates from one station to another.
Abstract: Aspects relate to automated cell culture incubators comprising imaging systems, e.g., holographic or phase-contrast imagers, configured for imaging said cells within the incubators.
Abstract: Provided herein are methods for decreasing dysbiosis, restoring the microbiome, and/or increasing recovery of a healthy microbiome (e.g. following a dysbiosis inducing event), by administering pharmaceutical compositions to a subject. Also provided are methods for protecting the microbiome of a subject and/or colonizing the microbiome of a subject by administering pharmaceutical compositions to the subject.
Type:
Grant
Filed:
August 16, 2019
Date of Patent:
December 10, 2024
Assignee:
Vedanta Biosciences, Inc.
Inventors:
Jason Norman, Bernat Olle, Bruce Roberts, Rajita Menon
Abstract: A compact sorting flow cytometer system is disclosed. The system includes a flow cell and a deflection unit in communication with the flow cell to receive charged drops and uncharged drops in a stream of a sample biological fluid. The deflection unit includes a case having a deflection cone and chamber, a tub with a drain, and a slot in a base. The deflection unit further includes electrostatic charge plates in the cone forming an electrostatic charge field; and first and second pivotal scuppers, and a center non-pivotal collector arranged along a shaft in the tub of the case. Uncharged drops pass the electrostatic charge field undeflected in a center stream path while charged drops are deflected away from it. The pivotal scuppers pivot between positions to direct charged drops into the tub for aspiration or to pass through the slot in the base for collection.
Type:
Grant
Filed:
May 31, 2022
Date of Patent:
December 10, 2024
Assignee:
Cytek Biosciences, Inc.
Inventors:
Glen Krueger, David Vrane, Kuncheng Wang, Qiuta Gu
Abstract: A biological fluid filtration system for scanning a biological fluid so as to filter potentially undesirable constituents from the biological fluid for therapeutic or diagnostic purposes. The biological fluid filtration system generally includes a fluid receiving device adapted to receive a biological fluid. A valve including an inlet, a first outlet, and a second outlet is fluidly connected to the fluid receiving device. The biological fluid within the fluid receiving device is scanned by a scanner to produce scanned data relating to the biological fluid. A control unit in communication with the scanner and the valve receives the scanned data and controls the valve based on the scanned data. The valve is controlled to direct the biological fluid through either the first or second outlet of the valve depending upon the constituents of the biological fluid identified by the control unit.
Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-Crel-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-Crel-derived meganuclease business.
Abstract: The present invention provides methods for using drain fluid obtained from medical procedures to assess diagnostic biomarkers indicative of disease obtained from drain fluid. In some embodiments, the diagnostics biomarkers are cell-free nucleic acids. In some embodiments, the disease is cancer. In some embodiments, a library of cfDNA is prepared and/or sequenced. In some embodiments, the methods comprise extracting nucleic acid from surgical drain fluid; conducting a size selection procedure to isolate cell-free nucleic acid from the surgical drain fluid; and detecting the cell-free nucleic acid.
Type:
Grant
Filed:
April 16, 2024
Date of Patent:
December 3, 2024
Assignee:
Droplet Biosciences, Inc.
Inventors:
Wendy Winckler Adamovich, Seka Lazare, Damion L. Whitfield, Megan Elisabeth Long
Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.